From: Metabolic syndrome and its components in patients with psoriasis
MS | No MS | P | |
---|---|---|---|
Mean ± SD | Mean ± SD | ||
Median (minimal-maximal values) | Median (minimal-maximal values) | ||
Age (years) | 55.45 ± 11.28 | 42.69 ± 13.16 | <0.001 |
BMI (kg/m2) | 30.5 (22.5-41.79) | 25.52 (18.9-36.36) | <0.001 |
HOMA Index | 3.79 (1.07-22.73) | 1.94 (0.85-6.97) | <0.001 |
Age at time of diagnosis (years) | 34.25 ± 16.29 | 24.6 ± 13.5 | 0.002 |
Time of evolution (years) | 20 (0.5-55) | 15 (1-51) | ns |
PASI Index | 6.95 (0-35) | 4.8 (0-36.3) | ns |
Moderate - Severe Psoriasis | 24/53 (45.2%) | 18/48 (36.7%) | ns |
Psoriatic Arthritis (%) | 22.64% | 18.3% | ns |
Topical corticosteroids | 54.71% | 71.4% | |
Immunosupressors | 4 methotrexate | 1 leflunamide | |
1 methotrexate + deflazacort | |||
Biolological treatment | - | 2 adalimumab |